{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:06:25Z","timestamp":1794006385153,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Grants-in-Aid for Exploratory Research","award":["20KK0192"],"award-info":[{"award-number":["20KK0192"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-025-01409-w","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:34:47Z","timestamp":1765460087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-radiation targeting of TIGIT and CD96 improved immunotherapy efficacy in head and neck squamous cell carcinoma"],"prefix":"10.1186","volume":"32","author":[{"given":"Mohammed","family":"Salah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naritoshi","family":"Mukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shinomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nen-ichi","family":"Nibu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"1409_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/S41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574:696\u2013701. https:\/\/doi.org\/10.1038\/S41586-019-1671-8.","journal-title":"Nature"},{"key":"1409_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.JIM.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15\u201322. https:\/\/doi.org\/10.1016\/J.JIM.2004.08.008.","journal-title":"J Immunol Methods"},{"key":"1409_CR3","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","volume":"371","author":"A Argiris","year":"2008","unstructured":"Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695. https:\/\/doi.org\/10.1016\/S0140-6736(08)60728-X.","journal-title":"Lancet"},{"key":"1409_CR4","doi-asserted-by":"publisher","first-page":"1001161","DOI":"10.3389\/FIMMU.2022.1001161\/FULL","volume":"13","author":"H Baysal","year":"2022","unstructured":"Baysal H, Siozopoulou V, Zaryouh H, Hermans C, Lau HW, Lambrechts H, Fransen E, De Pauw I, Jacobs J, Peeters M, Pauwels P, Vermorken JB, Smits E, Lardon F, De Waele J, Wouters A. The prognostic impact of the immune signature in head and neck squamous cell carcinoma. Front Immunol. 2022b;13:1001161. https:\/\/doi.org\/10.3389\/FIMMU.2022.1001161\/FULL.","journal-title":"Front Immunol"},{"key":"1409_CR5","doi-asserted-by":"publisher","unstructured":"Baysal H, Siozopoulou V, Zaryouh H, Hermans C, Lau HW, Lambrechts H, Fransen E, De Pauw I, Jacobs J, Peeters M, Pauwels P, Vermorken JB, Smits E, Lardon F, De Waele J, Wouters A. The prognostic impact of the immune signature in head and neck squamous cell carcinoma. Front Immunol. 2022a;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1001161.","DOI":"10.3389\/FIMMU.2022.1001161"},{"key":"1409_CR6","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","volume":"22","author":"SJ Blake","year":"2016","unstructured":"Blake SJ, Dougall WC, Miles JJ, Teng MWL, Smyth MJ. Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy. Clin Cancer Res. 2016;22:5183\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0933.","journal-title":"Clin Cancer Res"},{"key":"1409_CR7","doi-asserted-by":"publisher","unstructured":"Boieri M, Malishkevich A, Guennoun R, Marchese E, Kroon S, Trerice KE, Awad M, Park JH, Iyer S, Kreuzer J, Haas W, Rivera MN, Demehri S. CD4\u2009+\u2009T helper 2 cells suppress breast cancer by inducing terminal differentiation. J Exp Med. 2022;219. https:\/\/doi.org\/10.1084\/JEM.20201963.","DOI":"10.1084\/JEM.20201963"},{"key":"1409_CR8","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","volume":"29","author":"AK Chaturvedi","year":"2011","unstructured":"Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the united States. J Clin Oncol. 2011;29:4294\u2013301. https:\/\/doi.org\/10.1200\/JCO.2011.36.4596.","journal-title":"J Clin Oncol"},{"key":"1409_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/EJI.201948405","volume":"50","author":"EY Chiang","year":"2020","unstructured":"Chiang EY, de Almeida PE, de Almeida Nagata DE, Bowles KH, Du X, Chitre AS, Banta KL, Kwon Y, McKenzie B, Mittman S, Cubas R, Anderson KR, Warming S, Grogan JL. CD96 functions as a co-stimulatory receptor to enhance CD8\u2009+\u2009T cell activation and effector responses. Eur J Immunol. 2020;50:891\u2013902. https:\/\/doi.org\/10.1002\/EJI.201948405.","journal-title":"Eur J Immunol"},{"key":"1409_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Tiragolumab plus Atezolizumab versus placebo plus Atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23:781\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(22)00226-1.","journal-title":"Lancet Oncol"},{"key":"1409_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/imr.12518","volume":"276","author":"WC Dougall","year":"2017","unstructured":"Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112\u201320. https:\/\/doi.org\/10.1111\/imr.12518.","journal-title":"Immunol Rev"},{"key":"1409_CR12","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 Blockade. Cancer Res. 2014;74:5458\u201368. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1258.","journal-title":"Cancer Res"},{"key":"1409_CR13","doi-asserted-by":"publisher","unstructured":"Feng S, Isayev O, Werner J, Bazhin AV. CD96 as a potential immune regulator in cancers. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/IJMS24021303.","DOI":"10.3390\/IJMS24021303"},{"key":"1409_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.ORALONCOLOGY.2018.04.008","volume":"81","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of checkmate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45\u201351. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2018.04.008.","journal-title":"Oral Oncol"},{"key":"1409_CR15","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22877.1","author":"L Gorvel","year":"2020","unstructured":"Gorvel L, Olive D. Targeting the PVR-TIGIT axis with immune checkpoint therapies. F1000Res 9. 2020. https:\/\/doi.org\/10.12688\/f1000research.22877.1.","journal-title":"F1000Res 9"},{"key":"1409_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, de Olza MO, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Rodrigo BN, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Laniti DD, Irving M, Coukos G. Low-Dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12:108\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0003.","journal-title":"Cancer Discov"},{"key":"1409_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/S43018-020-0036-4","volume":"1","author":"ME Hoekstra","year":"2020","unstructured":"Hoekstra ME, Bornes L, Dijkgraaf FE, Philips D, Pardieck IN, Toebes M, Thommen DS, van Rheenen J, Schumacher TNM. Long-distance modulation of bystander tumor cells by CD8\u2009+\u2009T cell-secreted IFN\u03b3. Nat Cancer. 2020;1:291. https:\/\/doi.org\/10.1038\/S43018-020-0036-4.","journal-title":"Nat Cancer"},{"key":"1409_CR18","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/S41388-020-1250-3","volume":"39","author":"MKND Hutchinson","year":"2020","unstructured":"Hutchinson MKND, Mierzwa M, D\u2019Silva NJ. Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer. Oncogene. 2020;39:3638\u201349. https:\/\/doi.org\/10.1038\/S41388-020-1250-3.","journal-title":"Oncogene"},{"key":"1409_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5483\/BMBREP.2021.54.1.229","volume":"54","author":"H Jin","year":"2021","unstructured":"Jin H, seung, Park Y. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep. 2021;54:2\u201311. https:\/\/doi.org\/10.5483\/BMBREP.2021.54.1.229.","journal-title":"BMB Rep"},{"key":"1409_CR20","doi-asserted-by":"publisher","first-page":"41242","DOI":"10.18632\/ONCOTARGET.17168","volume":"8","author":"KJ Kim","year":"2017","unstructured":"Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 2017;8:41242\u201355. https:\/\/doi.org\/10.18632\/ONCOTARGET.17168.","journal-title":"Oncotarget"},{"key":"1409_CR21","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.3390\/IJMS21218151","volume":"21","author":"S Kumari","year":"2020","unstructured":"Kumari S, Mukherjee S, Sinha D, Abdisalaam S, Krishnan S, Asaithamby A. Immunomodulatory effects of radiotherapy. Int J Mol Sci. 2020;21:8151. https:\/\/doi.org\/10.3390\/IJMS21218151.","journal-title":"Int J Mol Sci"},{"key":"1409_CR22","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.7150\/THNO.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5265\u201386. https:\/\/doi.org\/10.7150\/THNO.58390.","journal-title":"Theranostics"},{"key":"1409_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/1878-0261.12029","volume":"11","author":"JF Liu","year":"2017","unstructured":"Liu JF, Ma SR, Mao L, Bu LL, Yu GT, Li YC, Huang CF, Deng WW, Kulkarni AB, Zhang WF, Sun ZJ. T-cell Immunoglobulin mucin 3 Blockade drives an antitumor immune response in head and neck cancer. Mol Oncol. 2017;11:235\u201347. https:\/\/doi.org\/10.1002\/1878-0261.12029.","journal-title":"Mol Oncol"},{"key":"1409_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/S13046-018-0713-7","author":"JF Liu","year":"2018","unstructured":"Liu JF, Wu L, Yang LL, Deng WW, Mao L, Wu H, Zhang WF, Sun ZJ. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J Exp Clin Cancer Res 37. 2018. https:\/\/doi.org\/10.1186\/S13046-018-0713-7.","journal-title":"J Exp Clin Cancer Res 37"},{"key":"1409_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/J.MAYOCP.2015.12.017","volume":"91","author":"S Marur","year":"2016","unstructured":"Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on Epidemiology, Diagnosis, and treatment. Mayo Clin Proc. 2016;91:386\u201396. https:\/\/doi.org\/10.1016\/J.MAYOCP.2015.12.017.","journal-title":"Mayo Clin Proc"},{"key":"1409_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/J.SEMRADONC.2019.12.004","volume":"30","author":"AM Monjazeb","year":"2020","unstructured":"Monjazeb AM, Schalper KA, Villarroel-Espindola F, Nguyen A, Shiao SL, Young K. Effects of radiation on the tumor microenvironment. Semin Radiat Oncol. 2020;30:145. https:\/\/doi.org\/10.1016\/J.SEMRADONC.2019.12.004.","journal-title":"Semin Radiat Oncol"},{"key":"1409_CR27","doi-asserted-by":"publisher","unstructured":"Mori M, Kanayama M, Kuwata T, Manabe T, Nemoto Y, Nishizawa N, Oyama R, Matsumiya H, Nabe Y, Taira A, Takenaka M, Yoneda K, Kuroda K, Tanaka F. Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy. Sci Rep. 2023;13. https:\/\/doi.org\/10.1038\/S41598-023-29724-4.","DOI":"10.1038\/S41598-023-29724-4"},{"key":"1409_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4049\/JIMMUNOL.182.3.1429","volume":"182","author":"SC Morris","year":"2009","unstructured":"Morris SC, Heidorn SM, Herbert DR, Perkins C, Hildeman DA, Khodoun MV, Finkelman FD. Endogenously produced IL-4 nonredundantly stimulates CD8\u2009+\u2009T cell proliferation. J Immunol. 2009;182:1429. https:\/\/doi.org\/10.4049\/JIMMUNOL.182.3.1429.","journal-title":"J Immunol"},{"key":"1409_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.CLIM.2018.01.003","volume":"188","author":"A Narsale","year":"2018","unstructured":"Narsale A, Moya R, Davies JD. Human CD4\u2009+\u2009CD25\u2009+\u2009CD127hi cells and the Th1\/Th2 phenotype. Clin Immunol. 2018;188:103\u201312. https:\/\/doi.org\/10.1016\/J.CLIM.2018.01.003.","journal-title":"Clin Immunol"},{"key":"1409_CR30","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/CAS.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080. https:\/\/doi.org\/10.1111\/CAS.14069.","journal-title":"Cancer Sci"},{"key":"1409_CR31","doi-asserted-by":"publisher","unstructured":"Parmar K, Mohamed A, Vaish E, Thawani R, Cetnar J, Thein KZ. Immunotherapy in head and neck squamous cell carcinoma: an updated review. Cancer Treat Res Commun. 2022;33. https:\/\/doi.org\/10.1016\/J.CTARC.2022.100649.","DOI":"10.1016\/J.CTARC.2022.100649"},{"key":"1409_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1146\/ANNUREV-CANCERBIO-030419-033428\/CITE\/REFWORKS","volume":"4","author":"G Plitas","year":"2020","unstructured":"Plitas G, Rudensky AY. Regulatory T cells in cancer. Annu Rev Cancer Biol. 2020;4:459\u201377. https:\/\/doi.org\/10.1146\/ANNUREV-CANCERBIO-030419-033428\/CITE\/REFWORKS.","journal-title":"Annu Rev Cancer Biol"},{"key":"1409_CR33","doi-asserted-by":"publisher","unstructured":"Qian JM, Schoenfeld JD. Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol. 2021a;10. https:\/\/doi.org\/10.3389\/FONC.2020.608772.","DOI":"10.3389\/FONC.2020.608772"},{"key":"1409_CR34","doi-asserted-by":"publisher","unstructured":"Qian JM, Schoenfeld JD. Radiotherapy and immunotherapy for head and neck cancer: current evidence and challenges. Front Oncol. 2021b;10. https:\/\/doi.org\/10.3389\/FONC.2020.608772.","DOI":"10.3389\/FONC.2020.608772"},{"key":"1409_CR35","doi-asserted-by":"publisher","first-page":"2204951","DOI":"10.1002\/ADVS.202204951","volume":"10","author":"J Qiu","year":"2023","unstructured":"Qiu J, Qu X, Wang Y, Guo C, Lv B, Jiang Q, Su W, Wang L, Hua K. Single-Cell landscape highlights heterogenous Microenvironment, novel immune reaction Patterns, potential biomarkers and unique therapeutic strategies of cervical squamous Carcinoma, human Papillomavirus-Associated (HPVA) and Non-HPVA adenocarcinoma. Adv Sci. 2023;10:2204951. https:\/\/doi.org\/10.1002\/ADVS.202204951.","journal-title":"Adv Sci"},{"key":"1409_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/S41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8\u2009+\u2009T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367. https:\/\/doi.org\/10.1038\/S41416-020-01048-4.","journal-title":"Br J Cancer"},{"key":"1409_CR37","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.23.01363","volume":"42","author":"CM Rudin","year":"2024","unstructured":"Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. SKYSCRAPER-02: tiragolumab in combination with Atezolizumab plus chemotherapy in untreated Extensive-Stage Small-Cell lung cancer. J Clin Oncol. 2024;42:324\u201335. https:\/\/doi.org\/10.1200\/JCO.23.01363.","journal-title":"J Clin Oncol"},{"key":"1409_CR38","doi-asserted-by":"publisher","unstructured":"Saddawi-Konefka R, Simon AB, Sumner W, Sharabi A, Mell LK, Cohen EEW. Defining the role of immunotherapy in the curative treatment of locoregionally advanced head and neck cancer: Promises, Challenges, and opportunities. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/FONC.2021.738626.","DOI":"10.3389\/FONC.2021.738626"},{"key":"1409_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. Stereotactic radiation therapy augments antigen-Specific PD-1-Mediated antitumor immune responses via Cross-Presentation of tumor antigen. Cancer Immunol Res. 2015;3:345\u201355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0196.","journal-title":"Cancer Immunol Res"},{"key":"1409_CR40","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/CURRONCOL29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044. https:\/\/doi.org\/10.3390\/CURRONCOL29050247.","journal-title":"Curr Oncol"},{"key":"1409_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/S41417-020-0183-X","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4\u2009+\u2009T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28:5\u201317. https:\/\/doi.org\/10.1038\/S41417-020-0183-X.","journal-title":"Cancer Gene Ther"},{"key":"1409_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/82771","volume":"1","author":"M Terabe","year":"2000","unstructured":"Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofskv JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol. 2000;1:515\u201320. https:\/\/doi.org\/10.1038\/82771.","journal-title":"Nat Immunol"},{"key":"1409_CR43","doi-asserted-by":"publisher","unstructured":"Trumet L, Weber M, Hahn A, Kunater L, Geppert C, Glajzer J, Struckmeier AK, M\u00f6st T, Lutz R, Kesting M, Ries J. The immune checkpoint receptor CD96: A local and systemic immune modulator in oral cancer? Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/CANCERS15072126.","DOI":"10.3390\/CANCERS15072126"},{"key":"1409_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/NRI3839","volume":"15","author":"I Voskoboinik","year":"2015","unstructured":"Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15:388\u2013400. https:\/\/doi.org\/10.1038\/NRI3839.","journal-title":"Nat Rev Immunol"},{"key":"1409_CR45","doi-asserted-by":"publisher","first-page":"11350","DOI":"10.3390\/MOLECULES190811350","volume":"19","author":"X-A Wang","year":"2014","unstructured":"Wang X-A, Xiang S-S, Li H-F, Wu X-S, Li M-L, Shu Y-J, Zhang F, Cao Y, Ye Y-Y, Bao R-F, Weng H, Wu W-G, Mu J-S, Hu Y-P, Jiang L, Tan Z-J, Lu W, Wang P, Liu Y-B. Cordycepin induces S phase arrest and apoptosis in human gallbladder cancer cells. Molecules. 2014;19:11350. https:\/\/doi.org\/10.3390\/MOLECULES190811350.","journal-title":"Molecules"},{"key":"1409_CR46","doi-asserted-by":"publisher","unstructured":"Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Ebstein S, Cortez C, Lowy I, Murphy AJ, Sleeman MA, Skokos D. Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol. 2021;6. https:\/\/doi.org\/10.1126\/SCIIMMUNOL.ABG0117.","DOI":"10.1126\/SCIIMMUNOL.ABG0117"},{"key":"1409_CR47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/NI.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u20139. https:\/\/doi.org\/10.1038\/NI.2035.","journal-title":"Nat Immunol"},{"key":"1409_CR48","doi-asserted-by":"publisher","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V. and M. Gillison. 2022. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable Local-Regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res 28:1345\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3351","DOI":"10.1158\/1078-0432.CCR-21-3351"},{"key":"1409_CR49","doi-asserted-by":"publisher","unstructured":"Woody S, Hegde A, Arastu H, Peach MS, Sharma N, Walker P, Ju AW. Survival is worse in patients completing immunotherapy prior to SBRT\/SRS compared to those receiving it concurrently or after. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/FONC.2022.785350.","DOI":"10.3389\/FONC.2022.785350"},{"key":"1409_CR50","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","volume":"7","author":"L Wu","year":"2019","unstructured":"Wu L, Mao L, Liu JF, Chen L, Yu GT, Yang LL, Wu H, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ. Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res. 2019;7:1700\u201313. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0725.","journal-title":"Cancer Immunol Res"},{"key":"1409_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/S13046-021-02068-5","author":"B Wu","year":"2021","unstructured":"Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, Yu Y, Zhang H, Xu F, Tian Y. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy. J Exp Clin Cancer Res 40. 2021. https:\/\/doi.org\/10.1186\/S13046-021-02068-5.","journal-title":"J Exp Clin Cancer Res 40"},{"key":"1409_CR52","doi-asserted-by":"publisher","unstructured":"Wu C, Te WC, Chen YH, Chang WY, Lin, Chen MF. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6. https:\/\/doi.org\/10.1038\/SREP19740.","DOI":"10.1038\/SREP19740"},{"key":"1409_CR53","doi-asserted-by":"publisher","unstructured":"Xin H, Liu Y, Chen P, Yin T, Wang M, Liu T, Wen Z, Cheng Y. CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway. Discover Oncol. 2022;13. https:\/\/doi.org\/10.1007\/S12672-022-00515-Z.","DOI":"10.1007\/S12672-022-00515-Z"},{"key":"1409_CR54","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","volume":"26","author":"ZZ Yang","year":"2020","unstructured":"Yang ZZ, Kim HJ, Wu H, Jalali S, Tang X, Krull JE, Ding W, Novak AJ, Ansell SM. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and Anti-PD-1 response in follicular lymphoma. Clin Cancer Res. 2020;26:5217\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0558.","journal-title":"Clin Cancer Res"},{"key":"1409_CR55","doi-asserted-by":"publisher","unstructured":"Ye W, Luo C, Liu F, Liu Z, Chen F. CD96 correlates with immune infiltration and impacts patient prognosis: A Pan-Cancer analysis. Front Oncol. 2021a;11. https:\/\/doi.org\/10.3389\/FONC.2021.634617\/FULL.","DOI":"10.3389\/FONC.2021.634617\/FULL"},{"key":"1409_CR56","doi-asserted-by":"publisher","unstructured":"Ye W, Luo C, Liu F, Liu Z, Chen F. CD96 correlates with immune infiltration and impacts patient prognosis: A Pan-Cancer analysis. Front Oncol. 2021b;11. https:\/\/doi.org\/10.3389\/FONC.2021.634617.","DOI":"10.3389\/FONC.2021.634617"},{"key":"1409_CR57","doi-asserted-by":"publisher","unstructured":"Yu C, Li Q, Zhang Y, Wen ZF, Dong H, Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022;10. https:\/\/doi.org\/10.3389\/FCELL.2022.941750.","DOI":"10.3389\/FCELL.2022.941750"},{"key":"1409_CR58","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/J.CCELL.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33:581. https:\/\/doi.org\/10.1016\/J.CCELL.2018.03.005.","journal-title":"Cancer Cell"},{"key":"1409_CR59","doi-asserted-by":"publisher","unstructured":"Zhang L, Wang WQ, Chen JH, Feng J, Liao YZ, Zou Y, Liu R. Tumor-infiltrating immune cells and survival in head and neck squamous cell carcinoma: a retrospective computational study. Sci Rep. 2024;14. https:\/\/doi.org\/10.1038\/S41598-024-56738-3.","DOI":"10.1038\/S41598-024-56738-3"},{"key":"1409_CR60","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.3389\/FIMMU.2018.02821\/FULL","volume":"9","author":"XM Zhou","year":"2018","unstructured":"Zhou XM, Li WQ, Wu YH, Han L, Cao XG, Yang XM, Wang HF, Zhao WS, Zhai WJ, Qi YM, Gao YF. Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivoby suppressing the function of NK and CD8\u2009+\u2009T cells. Front Immunol. 2018;9:2821. https:\/\/doi.org\/10.3389\/FIMMU.2018.02821\/FULL.","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1186\/s10020-026-01447-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01409-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01409-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01409-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:38:07Z","timestamp":1773920287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-025-01409-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01409-w","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10020-026-01447-y","URL":"https:\/\/doi.org\/10.1186\/s10020-026-01447-y","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Kobe University Hospital (approval number: B200007). Written informed consent for participation was obtained from all the patients. All animal experiments were approved by the Kobe University Hospital\u2019s Ethics Committee, Kobe City, Japan (approval number: P191001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}